CDP323
- Generic Name
- CDP323
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 9A54BAZ0YA
- Background
CDP323 is an antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple Sclerosis (MS). It is considered a small-molecule prodrug. CDP323 was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.
- Indication
Investigated for use/treatment in multiple sclerosis.
- Associated Conditions
- -
- Associated Therapies
- -
CDP323 Biomarker Study
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2011-09-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 71
- Registration Number
- NCT00726648
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323
- First Posted Date
- 2007-06-11
- Last Posted Date
- 2011-09-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 232
- Registration Number
- NCT00484536
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath